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Abstract
In order to assess the prognostic value of family history (FH) of malignancies in patients afflicted with breast
cancer (BC), we examined FH and histopathologic characteristics of 542 Iranian primary BC patients. Cases with
distant metastasis at the time of diagnosis were excluded. Mean age of the studied population was 49 and the most
common presenting stage was stage IIA followed by stage IIB.
Data on a total of 6089 relatives (1st to 4th generations with the assumption of probands as the 3rd generation)
were gathered.  FH of BC and other malignancies (OM) was positive in 29 and 54% of cases, respectively. The most
common OM’s were  gastric (67), lung (52) and uterus (47) cancers.
We found that a FH of BC does not have any significant correlation with proven prognostic factors but a history
of BC among relatives at or before the age of 36 is associated with more aggressive tumours. On the other hand,
although FH of OM was associated with an older age of the probands (which is generally associated with a favourable
prognosis), tumours of the cases with FH of OM had higher grades,  lymphatic invasion being detected more frequently.
Also we noted that the younger the age of the relatives diagnosed with cancer, the higher the stage of the probands
themselves.
All together our study indicates the possibility of a relation between FH of BC and OM, and histopathologic
characteristics of the probands’ tumours which would put forward FH as a prognostic factor rather than a simple
risk factor in BC.
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Data presented in this article have been previously
presented in the 22rd Annual Meeting of the International
Association of Cancer Registeries, 8-10 November 2000,
Thailand (Atri et al and Mehdipour et al), 3rd Global
Conference for Cancer Organisations, 24-27 June, UK (Atri
et al) and 23rd Annual Meeting of International Association
of Cancer Registries, 27 August, Cuba (Atri et al).
Abbreviations: Family History (FH), Breast Cancer
(BC), Malignancies other than Breast Cancer (OM).
Background
The high frequency of breast cancer (BC) and its role as
the second leading lethal cancer (after lung cancer)  (Andreoli
et al., 2001) has provoked much attention to develop
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strategies for risk assessment (and identifying high risk
populations), early detection, predicting the individual
outcome and determining the usage of more aggressive
treatments.
In order to achieve these goals, identifying the risk factors
(which influence one's risk of developing breast cancer) and
the prognostic factors (which influence the patient’s outcome
and the severity of the disease) are two essential components.
Markers of prognosis perdict patient outcome irrespective
of the treatment given (McGuire and Clark, 1992; Gasparini,
1998; Hayes et al., 1998). In general, such factors reflect
biologic characteristics of the tumours including
proliferation, invasion, and mobility (Isaacs et al., 2001).
Using prognostic factors, patients with early stage breast
cancer might be assigned to one of several deifferent
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outcome categories (Hayes et al., 1998), which in turn may
guide systemic treatment recommendations. These
prognostic factors are classified into three different
categories based upon the predictive strength of the factor
(Table 1).
The most important risk factors of BC include older age,
positive family history (FH), early menarche, late
menopause, first term pregnancy after age 25 years, null
parity, exposure to radiation (as in radiotherapy), and perhaps
use of exogenous estrogen (Andreoli et al., 2001).  Moreover,
epidemiological studies have suggested some dietary factors
(such as high fat intake) as other risk factors, but the causative
links remain to be revealed (Andreoli et al., 2001).
Of all these factors, the FH is perhaps the oldest and the
most attractive issue. A positive FH of BC is defined as
having one or more blood relatives who have, or have had
BC. These relatives could be on either the father or mother's
side of the family. Relatives by marriage (in-laws) or by
adoption do not count in determining the family risk of
disease. (Breast Cancer and Family History, 1997) Talking
about the importance of FH of BC in increasing the risk, it
is essential to know:
• The number of relatives with breast cancer
• How many close relatives (first degree relatives) have
or have had breast cancer
• The age that the breast cancer was diagnosed (Breast
Cancer and Family History, 1997).
Identification of BC susceptibility genes, BRCA1 and
BRCA2, raised hope to reveal the underlying mechanisms
of BC inheritance but further studies showed that only 5 to
10% of BC cases are associated with these genes, while the
mutations themselves do not seem to have full penetrance
in carriers; Altogether it is indicating that other not yet fully
identified genetic and evironmental factors should be
responsible (Andreoli et al., 2001).
In cross-sectional studies of adult populations, 5% to
10% of women have a mother or sister with breast cancer,
and about twice as many have either a first-degree or a
second-degree relative with breast cancer. (Yang et al., 1998;
Colditz et al., 1993; Slattery and Kerber, 1993; Johnson et
al., 1995) The risk conferred by a family history of breast
cancer has been assessed in both case-control and cohort
studies, using volunteer and population-based samples, with
generally consistent results (Pharoah et al.,1997). In a pooled
analysis of 38 studies, the relative risk of breast cancer
conferred by a first-degree relative with breast cancer was
2.1 (95% confidence interval (CI) 2.0-2.2) (Pharoah et
al.,1997). Risk varies with the age at which the affected
relative was diagnosed: the younger the age of the affected
relative, the greater the risk posed to relatives (Yang et al.,
1998; Colditz et al., 1993; Slattery and Kerber, 1993; Pharoah
et al.,1997; Negri et al., 1997; Hemminki et al., 1998). This
effect was strongest for women under 50 who had a first-
degree relative affected before age 50 (Pharoah et al.,1997).
The number of affected relatives and the closeness of
their biologic relationship are also important factors (Colditz
et al., 1993; Slattery and Kerber, 1993; Pharoah et al.,1997).
In general, the greater the number of affected relatives and
the closer the biologic relationship, the greater the risk
(Colditz et al., 1993; Slattery and Kerber, 1993; Pharoah et
al.,1997). The number of female relatives in the family
influences both utility and significance of the family history.
In families with few women, it may be difficult to identify a
genetic susceptibility to cancer, even if a genetic
susceptibility is present. If a family has many female family
members, the proportion of affected to unaffected may be a
more important indicator of risk than the absolute number
of affected relatives.
Moreover, a few investigators have focused on the
possible link between having an FH of BC and the prognosis
of the disease, which would put forward FH as a prognostic
factor rather than a sole risk factor. In a study of 733 young
BC patients (Malone et al., 1996) researchers found that
women who had a first-degree family history of BC
experienced increased survival and this finding was not
attributable to differences in screening or treatment. More
recently, an other study (Mohammed et al., 1998) compared
the clinicopathological characteristics of breast tumours
between 95 FH (+) and 329 FH (-) women with BC and
found that there was a trend for the FH (+) patients to have
slightly smaller tumours (mean size 2.49 vs. 3.04 cm,
p=0.09) and also a significantly greater proportion of the
familial cases had grade III infiltrating ductal carcinoma
(40% vs. 27%, p=0.02). Despite this, there were more cases
of operable node-negative disease among the study group
than among the controls (48% vs. 32%, p=0.004) and there
was a highly significant survival advantage for patients with
a positive FH (p<0.001).
More distinct histopathologic differences are noted,
when the BRCA1 and 2 mutations are considered (Couch et
al., 1997; Shattuck-Eidens et al., 1997) : Both BRCA1 and
2 mutation carrier tumours are of higher grade than are
sporadic cases. An excess of medullary/atypical medullary
carcinoma has been reported in patients with BRCA1
mutations. Multifactorial analysis, however, shows that the
only features independently associated with BRCA1
mutations are a high mitotic count, pushing tumour margins
and a lymphocytic infiltrate. For BRCA2 mutation, an
association with tubular/lobular carcinoma has been
suggested, but not substantiated in a larger Breast Cancer
Linkage Consortium study. In multifactorial analysis, the
independent features were a lack of tubule formation and
pushing tumour margins only (Lakhani, 1999).
Table 1. Proven Breast Cancer Prognostic Factors.
Strength         Relative Risk             Prognostic Marker
          of recurence
Strong >2 TNM stage
>2 Axillary nodal status
>2 Tuomor size
Moderate 1.5-2 Tuomor grade
1.5-2 Lymphatic or vascular invasion
Weak 2> ER content
2> PR content
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Conversely, other study of 201 young early-stage BC
patients (Chabner et al., 1998) found that the rates of local,
regional and distant recurrence and disease-free or overall
survival did not differ between FH (+) and FH (-) patients
and these findings were confirmed in an other study too.
(Harrold et al., 1998) Moreover, in a review of 583 BC
patients (Tsuchiya et al., 1998) researchers didn’t find any
differences for any of mean age, menopausal status,
histological staging, and estrogen receptor status between
FH (+) and FH (-) patients.
Finally, considering the rather limited role of BRCA1/2
genes mutations in familial BC’s, an other group (Lakhani
et al., 2000) analyzed 82 BC patients from non-BRCA1/2
families and found out that BC’s in these families were of
significantly lower grade (p=0.001), showed less nuclear
pleomorphism (p=0.0002), and had a lower mitotic count
(p=0.003) in comparison with control BC unselected for a
FH of the disease.
But what is the role of the family history of other cancers
in this context? So far, the main focus has been on the
importance of FH of malignancies other than BC (OM) as
risk factors (including a previous article by the author (Atri
et al., 2001)) and the leading and most significant association
has been found between the FH of ovarian cancer and
increasing risk of BC.
A first-degree relative with ovarian cancer confers a
modest risk of BC, e.g., the odds ratio derived from a case-
control study based on the Utah Cancer Registry was 1.27
(95% CI 0.91-1.77), (Kerber and Slattery, 1995) and other
studies have found no evidence of increased risk (Negri et
al., 1997; Auranen et al., 1996). When the Utah data were
analyzed according to a FH score (based on characteristics
that included number of relatives with ovarian cancer, their
age of diagnosis, and biologic relatedness), however, the
odds ratio for women with a score of 5 or greater (3% of the
population) was 1.60 (95% CI 1.03-2.43), and for women
with scores of 2.0 to 4.9 (12% of the population), the odds
ratio was 1.15 (95% CI 1.01-1.36).[Kerber and Slattery,
1995] The presence of both breast and ovarian cancer in a
family increases the likelihood that a cancer-predisposing
mutation is present (Lakhani et al., 2000; Yang et al., 1998).
The other candidate cancers, associated with an increased
risk of BC occurance are uterus, colon and prostate cancers.
Yet, there exist much debate for (Andreoli et al., 2001;
Familial breast cancer risks, 1993; Andrieu et al., 1994;
Slattery and Kerber, 1994) or against (Familial breast cancer
risks, 1993; Andrieu et al., 1991; Lin et al., 1999) these
associations.
Our review of the literature and existing articles failed
to provide us with any notable reports regarding the possible
relation between FH of OM and the characteristics of the
patients tumours and their prognosis.
The last but not least thing to consider is the extend to
which the pedigrees and family hisrory-based data are
reliable. Most investigators attempt to confirm cancer
histories in relatives from medical records, cancer registries,
or death certificates. However, this is becoming increasingly
difficult with greater emphasis on confidentiality and early
destruction of hospital records (Evans et al., 1996). However,
mere relying on interviews with patients and their relatives
would subject the findings to some degrees of bias and
uncertainty.
Patients and Methods
In order to evaluate the relation between FH of breast
cancer (BC) and other malignancies (OM), and the
histopathologic characteristics of BC patients and the known
prognostic factors, we performed a retrospective study on a
database of 542 Iranian patients, diagnosed with primary
BC. Reqruitment was carried out from 1993 to 1999.
The patients were mostly middle to high class citizens
of Tehran, who were examined and followed up by a surgeon
in a private-practice outpatient clinic. The patients were put
through comprehensive clinical and paraclinical
investigation and suspected cases underwent biopsy and/or
total masectomy, if necessary. All of the cases received
adequate treatment according to the latest protocols.
Staging was performed using physical examination and
paraclinic findings (including radiologic studies and routine
blood tests), and patients with distant metastasis at the time
of diagnosis (stage IV) were excluded from the study.
Tumour slides were reviewed by a set of selected expert
pathologists and Estrogene and Progestrone receptors (ER
and PR, respectively) were analysed immunohistochemicaly
on samples from parafine embeded blocks of the tumours.
Patients and their relatives were interviewed by a
geneticist and detailed pedigrees were drawn for all the
patients. Each interview took an average of an hour. The
pedigrees include all healthy and diseased,  (wheater cancer
afflicted or not) and alive or dead family members from the
grand-parents to the patrients’ offspring genaration including
1st to 4th degree relatives of the probands. Family trees were
often drawn on the basis of patients and their relatives claims
and whenever possible, firm evidence (e.g. reports) was used
to increase the accuracy and reliability of the gathered data.
Altogether, detailed histopathologic and pedigree data
were used to construct the database which was subsequently
analysed using SPSS program (SPSS for Windows, Release
10.0.1, Standard Version, Copyright ” SPSS Inc., 1989-
1999). Depending on the type of the variables, suitable
statistical analysis (e.g. chi-square, t—test, ANOVA, and
regression-correlation) was applied.
Results
The patients included 536 women and 6 men with the
mean age of 49 (std  dev 11.22; range 15-82). Of these, 67
(12.5%) cases were diagnoses at the age of 36 or younger.
The tumours were mostly unilateral (502 vs. 16) with ductal
pathology (ductal 471[87.9%]; lobular 41[7.6%]; mixed
ductal and lobular 7[1.3]).
The tumours were mostly high grade (63.8%). Mean
tumour size was 3.28cm (std dev 4.2652; range microscopic
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to 25cm) (Fig 1). Axillary lymph node (ALN) involvement
was detected in 54.4% of the cases and perinodal invasion
was found in 25.9% of these cases (Fig 2). Stage was
calculated using conventional TNM criteria of American
Joint Committee on Cancer classification for breast cancer
(Doherty et al., 1997), with assumption of M=0 as explained
above (Fig 3).
Vascular and lymphatic invasion was found in 50% and
17% of the tumours, and 61% and 62.5% of the tumours
showed positive ER and PR staining respectively.
Data on a total of 6089 relatives (1st to 4th generation,
assuming 3rd generation as the probands’ generation) were
gathered (Fig 4). Rate of Consanguinity among patients and
their parents were 16 and 15.8% respectively.
A positive FH of BC was noted in 29% of cases’
pedigrees; A total of 219 BCs (excluding probands) were
found in these pedigrees (70 1st, 69 2nd, 75 3rd , and 5 4th
degree relatives afflicted). Of these, 31 pedigrees had at least
one BC case, diagnosed at the age of 36 or younger (9 first-
degree and 6 second-degree relatives of the probands).
Fifty-four percents of the patients had a positive FH of
OM with a total of 469 cases afflicted (179 1st, 162 2nd,
143 3rd, and 12 4th degree relatives). The most common
cancers in these pedigrees included gastric (67), lung (52),
uterus (47),  heamatopoietic (acute and chronic leukaemia)
227
207
69
0
50
100
150
200
250
N0 (45.1%) N1 (41.2%) N2 (13.7%)
Figure 2.  Axillary Nodal Involvement. (N0 = no regional
lymph node involvement, N1 = metastasis to movable
ipsilateral nodes, N2 = metastasis to ipsilateral nodes
fixed to one another or to other structures)
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Figure 3. TNM Staging of the Tumours.
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Figure 4. Total Number of Relatives in Pedigrees
According to Sex and Generation (Patients Excluded).
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Figure 1. Tumour Size Distribution in Studied
Population. (T0 = no evidence of the primary tumour;
T1 = tumour<2 cm, T2 = 2<tumour<5 cm, T3 =
tumour>5 and T4 = skin or chest wall involvement)
(41), brain (34), colorectal (30), esophagous (28) and prostate
(28), liver (25), lymphoid tissue(lymphoma) (24), thyroid
(15) and ovary (7) cancers.
Discussion
FH of BC was not associated with FH of OM (chi-
square=0.742, df=1) but considering the number of cases, it
was noted that with the number of BC cases increased, the
number of OM cases also increased in the pedigrees
(p<0.001).
Whilst age of the patients was independent of the FH of
BC, it was related to the FH of OM; Mean age of the patients
with FH of OM in their 1st degree relatives was significantly
higher than those without it (51.72 vs. 47.99 yrs., t=3.436,
df=535, sig.(2-tailed)=0.001, 95% CI of difference=1.5965-
5.85.92) (Table 2). The same effect was also noted
considering the total number of 1st degree cancer (including
BC) cases in pedigrees: 51.27 vs. 47.79 yrs. (t=3.442, df=535,
sig.=0.001).
Also, mean age of the patients with a positive FH of
prostate cancers and leukaemia was higher: For FH of
prostate cancer (28 cases) 54.65 vs. 48.69 (t=2.655, df=535,
sig.=0.008), and for leukaemia (41 cases) 52.33 vs. 48.72
(t=2.311, df=535, sig.=0.025). Same effect was noted among
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Although FH of BC or OM was not generally associated
with tumour size, an FH of BC at or before age of 36 among
1st & 2nd degree relatives (n=15) was associated with larger
tumour size (Mean tumour size 4.64 vs. 2.99 cm, t=2.381,
df=490, sig.=0.018). Interestingly, FH of BC or OM was
not associated with the duration of delay between patient’s
awareness of the warning sign, and visiting the doctor
(Average of 7.53 and 8.86 weaks for patients with positive
and negative FH of OM and 8.24 and 8 weaks for patients
with and without FH of BC respectively).
Vascular invasion was noted more among patients with
FH of BC, though the correlation was not significant
(p=0.078)(Table 5). It was also associated with the more
number of OM cases in the pedigrees in 3rd and 4th degree
relatives (p=0.03). Again, mean age of the BC-afflicted
relatives was less among patients who had detectable
vascular invasion in their tumours (50.97 vs. 56.19 yrs., t=-
2.04, df=151, p=0.043).
Moreover, lymphatic invasion was associated with FH
of OM (chi-square=9.794, df=1, sig.=0.002) (Table 6). Mean
number of OM cases per pedigree was 0.62 and 1.06 in
patients whose tumours had and didn’t have lymphatic
invasion respectively (t=-2.392, df=313, sig.=0.017) and the
correlation was more significant considering the 1st and 2nd
degree relatives (p=0.008). Also mean number of all cancers
(BC and OM) per pedigree was higher among patients whose
tumours had significant lymphatic invasion (0.28 vs. 0.52
for 1st degree [t=-2.16, df=313, sig.=0.031] and .57 vs. 1
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Figure 5. Patients’ Tumour Grade and FH of Cancers
other than BC.
cases with an FH of uterus cancers in their 1st degree
relatives(n=15)( 54.93 vs. 48.81, t=2.08, df=535,
sig.=0.037).
Most of the bilateral cases had FH of BC (chi-
square=5.45, df=1, sig.=0.019) (Table 3). Cases with FH of
OM had higher grade tumours (p=0.012) (Fig. 5).
Considering the number of cancers in each pedigree and
degree of relatives, the most significant correlation was noted
between the patients’ tumour grade and the number of
cancers in their 2nd degree relatives (p=0.026).
Patients with FH of prostate cancer (n=28) had lower
TNM stage, but the correlation was not highly significant
(p=0.053). On the other hand, stages of the patients who
had an FH of esophagous cancer (n=28) were significantly
(p=0.033) lower. Finally, younger mean age of the cancer-
afflicted relatives was associated with higher patients’ stages
(p=0.002) (Table 4), and more involvement of ALN (Mean
age of 51.61 and 57 yrs in patients with and without ALN
involvement respectively, t=-2.645, df=240, sig.=0.009).
Table 3. Bilateral Involvement and FH of BC.
  Positive FH        Negative FH             Total
UnilateraL 146 356 512
Bilateral 9 7 16
Total 155 363 528
Table 2. Mean Age of the Patients, and the Number of
OM’s in Their 1st Degree Relatives.
No. of    No. of     Mean age          Std.Dev.       St.Error
cancers          cases
0 394 47.99 11.59 0.58
1 115 50.89 9.87 .92
2 27 55.07 8.19 1.57
3 2 55 11.31 8.00
4 1 48
Total 539 48.98 11.22 0.48
Table 5. Vascular Invasion and FH of BC.
  FH(+)      FH(-)         Total
With vascular invasion 53 99 162
Without vascualr invasion 40 116 156
Total 93 215 318
Table 6. Lymphatic Invasion and FH of OM.
       FH(+)   FH(-)       Total
With lymphatic invasion 19 35 54
Without lymphatic invasion 147 104 251
Total 166 139 305
Table 4. Stages of the Patients and the Mean Age of their
Cancer-afflicted Relatives.
Patients’ stages         Mean rel.age       Std.Dev.           Std.Error
Stage I 61.03 14.96 2.88
Stage IIA 54.16 16.25 1.75
Stage IIB 54.09 15.14 1.84
Stage IIIA 49.87 16.15 2.58
Stage IIIB 46.51 16.54 4.98
Total 53.85 16.00 1.05
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for 2nd degree relatives[t=-2.73, df=313, sig.=0.007]).
ER and PR staining was not associated with FH of BC
or OM at all. However, tumours of the patients who had FH
of prostate or esophagous cancers were mostly ER positive
(p=0.025 and p=0.02 respectivly), though the limited number
of the cases restricts the validity of this finding.
Conclusions
Family history (FH) is  the most important and perhaps
one of the most controversial risk factors of breast cancer
(BC). A positive FH of BC and OM is a frequent finding
which could double the risk of BC occurance. Moreover, it
is readily accessible and does not necessitate time and money
consuming procedures. However, it takes patience, tact and
attention to draw a detailed and percise pedigree and also,
valid documents to confirm the diseased relatives among
the families; otherwise, it might be quite possible to take an
innocent mass for a malignant tumour. We believe that tight
family bounds and close relationship in Iranian families
could increase this validity.
Previous studies have showed that the tumour behaviour
of the patients with a FH of BC is somehow different, with
a trend towards a less aggressive state and better prognosis.
The reason is not clear, but it has been attributed to the
patients’ increased awareness of the disease, which would
lead to the earlier detection of the tumour.
However, we did not find any significant differences
between the time period between patients’ first detecting
the tumour, and visiting the physician, for cases with and
without FH of BC or OM. Also tumour size (which could
be used as a rough estimate of the course of the disease)
was not different among patients with and without FH of
BC and/or OM in our study. These findings suggest the
involvement of other causative factors.
Also the mere FH of BC was not associated with FH of
OM, the number of OM’s increased significantly with
number of BC’s in the pedigrees.
Cases with bilateral involvement mostly had FH of BC.
It is quite expectable since the same factor(s) which had
increased the incidence of BC among relatives could increase
the chance of BC occurance in other breast of the patient.
We found that patients who had a history of BC at or
before the age of 36 among their 1st and 2nd  degree relatives,
had also more aggressive tumours (i.e. bigger size and more
vascular invasion). This finding confirms the importance of
stratifying the BC afflicted relatives according to age together
with emphasis on the degree of relatives in risk assessment.
But perhaps the most striking finding of this study was
the impact of FH of other malignancies (OM) on patients’
tumour behaviour. Cases with FH of OM were significantly
older than the ones without it. According to the type of
cancers, this effect was noted among patients with FH of
prostate cancer and leukaemia and also uterus cancer among
their 1st degree relatives. Also, FH of esophagous cancer
(which is rather common in Iran) was associated with a lower
stage and more ER staining. ER staining was also noted
more among tumours of the patients with FH of prostate
cancer. These findings support the less aggressive nature of
these tumours.
On the other hand, FH of OM was associated with higher
grade of the patients’ tumour and also more lymphatic
invasion. Considering the consensus that older age of onset
is associated with better prognosis, the later finding seems
to pose us with a paradox.
Once again, taking a look at the age of the cancer afflicted
relatives was helpful; the younger the age of relatives
diagnosed with cancer, the higher the stage of the probands
themselves.
Prognostic value of FH of BC is perhaps not a new idea
and other investigators have worked on it (though there still
exists much work to do in this regard), but as our data show,
FH of OM might be an other prognostic factor in BC patients,
which could have complex effects on tumours’ behaviour,
regarding type of cancer and the age-degree of the afflicted
relatives. Further study will clarify details of this association.
But what will be the next step? Cancer occurance is the
result of a complicated interaction between the inherited
(genetic) and aquired (enviromental) factors. Presence of a
history of BC or OM in one’s family could be indicative of
the possibility that something is predisposing the family
members to cancer and the propability increases with the
number of detected cases.  But here, our main enigma is
that, “Are the factors which predispose the individuals to
BC the same factors that determine the invasiveness of the
occurred tumours?”
Our findings confirm that these two phenomena (i.e.
initiation and progression) are at least to some extent distinct
in BC and they function separately (sometimes even
opposingly). FH of BC and/or OM increases the odd of BC
occurance, but it is not essentially associated with a worse
prognosis. This scope might help in building a model of
progression from normal breast tissue toward benign and
precancerous lesions and eventually a fully invasive
malignant tumour, similar to the model which has been
suggested for colorectal carcinomas.
The authors are fully aware of the limitations of their
study. Relying on the patients’ and their relatives’ claims
and shortage of firm evidence, weaken the validity of the
pedigrees but we took advantage of reports whenever
possible. Also, rather low frequency of some cancers,
increases the occurance of accidental associations and
decreases the reproduciblity of the findings.
The patients are being continuously followed up but the
6-year time period between the inclusion of the first and the
last case has made it somehow difficult to assess the survival
indices of the patients in the present article.
Genetic analysis is another factor which would be helpful
in identifying the role of FH in BC. The patients and their
selected relatives are being analyzed and screened for
sporadic and familial mutations in namely BRCA1 and 2,
p53 and APC genes in both tumour and blood speciments.
Follow-up of the studied population and genetic analysis is
being carried out and will be published subsequently.
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